Skip to content

Celcuity CELC Other Income (Expense)

Other Income (Expense) at other companies

Eli Lilly logo
Eli LillyLLY
-$65M+72.8%
Gilead Sciences logo
Gilead SciencesGILD
$235M+172%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$60.6M+7.1%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$6.26M+112%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$3.26M+21.1%
CG Oncology logo
CG OncologyCGON
$6.19M-20.2%

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's other income (expense)?
Celcuity (CELC) reported other income (expense) of -$2.33M in Q1 2026.
How has Celcuity's other income (expense) changed year-over-year?
Celcuity's other income (expense) decreased by 170.1% year-over-year, from -$864K to -$2.33M.
What is the long-term trend for Celcuity's other income (expense)?
Over 3 years (2021 to 2025), Celcuity's other income (expense) has grown at a 57.2% compound annual growth rate (CAGR), from -$1.25M to -$4.85M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.